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Psammocarcinoma is a rare variant of serous carcinoma of the
ovaries and has a favourable prognosis resembling that of serous
borderline tumors [1].
A 60-year-old woman had a pelvic mass 20weeks size. Magnetic
resonance imaging (MRI) showed bilateral ovarian cysts with sus-
picious peritoneal deposits (Figure. 1A). Carbohydrate antigen 125
level was 1300 U/mL. Peritoneal ﬂuid cytology showed large cell
groups with high nucleocytoplasmic ratio, irregular nuclear bor-
ders, and indistinct nucleoli. A single psammoma body (PB) was
detected (Figure 1B). A diagnosis of ovarian carcinoma was offered.
Intraoperatively, bilateral large cystic ovarian masses were seen
with thickened omentum and multiple subdiaphragmatic deposits.
A biopsy of the omental deposits showed tumor composed of small
cuboidal to round cells arranged in a papillary, cribriform pattern.
The cells showed minimal pleomorphism and scant mitotic ﬁgures.
Abundant PBs were scattered throughout the ﬁbrous stroma and in
the tips of the papillae (Figure 1C). A diagnosis of metastatic
deposits of ovarian psammocarcinoma, International Federation of
Gynecology and Obstetrics (FIGO) Stage IIIc was given. Cytokeratin
7 and epithelial membrane antigen showed strong immunoreac-
tivity in tumor cells (Figure 1D and 1E) and none for cytokeratin 20,
calretinin, and desmin. Immunoreactivity for estrogen receptors
was seen in 75% of tumor cells (Figure 1F). The patient was given
tamoxifen and chemotherapy.
Patients with psammocarcinoma range in age from 36 years to
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neal viscera, or peritoneum; (2) no more than moderate nuclear
atypia; (3) the presence of nests of solid epithelial proliferations
no greater than 15 cells in diameter; and (4) PBs that replace
at least 75% of the papillae or epithelial nests [1]. In the ovaries,
the presence of destructive stromal invasion excludes serous
borderline tumors, and moderate cytologic atypia excludes
high-grade serous carcinoma. In peritoneal psammocarcinoma:
(1) both ovaries must be of normal size; (2) the extraovarian
involvement must be greater than the ovarian involvement; (3)
the ovarian component must be < 5 mm  5 mm within
the ovaries or conﬁned to the ovarian surface; and (4) the
cytological characteristics must be of the serous type [2].
Forty cases of psammocarcinoma have been reported with 17
cases in the ovaries [3]. Tumour site does not have prognostic
signiﬁcance. Ovarian psammocarcinoma, usually presents
with FIGO Stage III disease [3]. The immunohistochemistry
ﬁndings of psammocarcinoma of the peritoneum reported
by Singh et al [4] were similar to those in our case. Elevated levels
of carbohydrate antigen 125 are reported in ovarian as well
as peritoneal psammocarcinoma [3,5]. Gilks et al [1] reported a
90% 10-year survival rate for psammocarcinoma patients. Few
reports of aggressive psammocarcinoma are found in the litera-
ture [6]. The behaviour of psammocarcinoma resembles that of
borderline serous tumors [1]. Radiologically multiple calciﬁca-
tions are seen within the tumor and the metastatic deposits.
Extensive minute calciﬁcations on computed tomography scan
not detected on the abdominal X-ray, and sandy, coarsely gran-
ular appearance on enhanced T1-weighted MRI are reported [7].
In the present case, MRI did not show the coarsely granular
appearance.
Treatment of ovarian psammocarcinoma consists of surgery for
debulking. Adjuvant chemotherapy has not been shown to increase
survival [3]. Tamoxifen might achieve complete and sustained
response in selected cases [8].e and General Hospital, Off Katraj Bypass Highway Flyover, Narhe, Ambegaon, Pune,
y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. (A) Magnetic resonance imaging of the pelvis, with bilateral ovarian complex cystic hyperintense T2 lesions. (B) Large cell cluster with central psammoma body, high
nucleocytoplasmic ratio, irregular nuclear borders, and indistinct nucleoli (hematoxylin and eosin, 400). (C) Psammoma bodies scattered throughout the stroma and in the tips of
the papillae (hematoxylin and eosin, 400) (D) Immunopositivity for cytokeratin 7 (100). (E) Epithelial membrane antigen (400). (F) Estrogen receptor (400).
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